Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H I - J - K - L - M N - O - P - Q - R - S T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter B

GENERIC NAME

TRADE NAME

CONDITION

STUDY CODE

STUDY NAME

ACCESS TO STUDY / PROTOCOL

ACCESS TO RESULTS

BACILLUS CLAUSII

Enterogermina

Diarrhea

LPS16140

EPIC

EudraCT Number: 2020-000970-10

BACILLUS CLAUSII

Enterogermina

Diarrhea

ENTER_L_01125

PADRE

NCT00447161

BACILLUS CLAUSII

Enterogermina

Diarrhea

ENTER_L_01486

ENIGMA

NCT00457353

BACILLUS CLAUSII

Enterogermina

Gastrointestinal Diseases

LPS15198

BASTA

EudraCT: 2018-001355-12

BACILLUS CLAUSII

Enterogermina

Gastrointestinal Diseases

PM_L_0161

EFESO

EudraCT: 2005-004934-42

 

BACILLUS CLAUSII

Enterogermina

Infection

PM_L_0199

DIAMANTE

NCT00424905

BACILLUS CLAUSII

Enterogermina

Diarrhea

ENTERR06929

cadiLAc

EudraCT: 2016-003444-37

BACILLUS CLAUSII

Enterogermina

Diarrhea

LPS14914

KIDDIE

2016-005165-31

 

BACILLUS CLAUSII

Enterogermina

Irritable Bowel Syndrome

ENTERL08784

BaclauSII

2018-004519-31

 

BACTERIAL LYSATES

Pulmonarom

Medical Prevention Therapy

BACLY_L_03329

NA

NCT00599417

BAMADUTIDE

Not marketed

Diabetes Mellitus, Type 2

DRI13940

NA

NCT02973321

BAMADUTIDE

Not marketed

Diabetes Mellitus, Type 2

PDY15012

NA

NCT03376802

BAMADUTIDE

Not marketed

Diabetes  Mellitus, Type 2

PDY15264

NA

NCT03350191

BAMADUTIDE

Not marketed

Diabetes  Mellitus, Type 2

TDR13700

NA

NCT02411825

BAMADUTIDE

Not marketed

Diabetes  Mellitus, Type 2

TDR15516

NA

NCT03414736

BELUMOSUDIL

Rezurock 

Bioavailability

KD025-106

NA

NCT02557139

BELUMOSUDIL

Rezurock

Drug-drug Interaction Autoimmune Diseases Fibrotic Disease

KD025-107

NA

NCT03530995

BELUMOSUDIL

Rezurock

Autoimmune Diseases Fibrosis

KD025-108

NA

NCT03907540

BELUMOSUDIL

Rezurock

Chronic Graft Versus Host Disease (cGVHD)

KD025-208 / ACT17631

NA

NCT02841995

BELUMOSUDIL

Rezurock

Chronic Graft Versus Host Disease (cGVHD)

KD025-213 / DRI17633

NA

NCT03640481

BELUMOSUDIL

Not Marketed

Psoriasis Vulgaris

KD025-205/ACT17656

NA

NCT02106195

BELUMOSUDIL

Not Marketed

Psoriasis Vulgaris

KD025-206/DFI17657

NA

NCT02317627

BELUMOSUDIL

Not Marketed

Chronic Plaque Psoriasis

KD025-211/EFC17658

NA

NCT02852967

BIVV001

Not marketed

Hemophilia A

TDU16220

NA

NCT03205163


References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted